Tina DeNofrio, RN, BSN, OCN
Dana-Farber Cancer InstituteHarvard Medical School
Boston, MA
Authored Items
November 2021 Vol 12, No 11
Prostate cancer (PCa) patients treated with injectable androgen deprivation therapy (ADT) are particularly vulnerable during a pandemic because they may not be able to self-administer treatment and may be required to visit a clinic/hospital for injections.
Tina DeNofrio, RN, BSN, OCN, Stuart N. Atkinson, MB, ChB, Deborah M. Boldt-Houle, PhD, Julia Vandross, NP-BC, BSN, MSN
November 2020 Vol 11, No 11
Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used androgen deprivation therapy (ADT) for prostate cancer (PCa).
Julia Vandross, NP-BC, BSN, MSN, Stuart N. Atkinson, MB, ChB, Deborah M. Boldt-Houle, PhD, Tina DeNofrio, RN, BSN, OCN
November 2019 Vol 10, No 11
Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used drugs for the delivery of androgen deprivation therapy (ADT) in prostate cancer (PCa).
Last modified: December 17, 2021